Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyung-Soo | - |
dc.contributor.author | Han, Kyung Ah | - |
dc.contributor.author | Kim, Tae Nyun | - |
dc.contributor.author | Park, Cheol-Young | - |
dc.contributor.author | Park, Jung Hwan | - |
dc.contributor.author | Kim, Sang Yong | - |
dc.contributor.author | Kim, Yong Hyun | - |
dc.contributor.author | Song, Kee Ho | - |
dc.contributor.author | Kang, Eun Seok | - |
dc.contributor.author | Kim, Chul Sik | - |
dc.contributor.author | Koh, Gwanpyo | - |
dc.contributor.author | Kang, Jun Goo | - |
dc.contributor.author | Kim, Mi Kyung | - |
dc.contributor.author | Han, Ji Min | - |
dc.contributor.author | Kim, Nan Hee | - |
dc.contributor.author | Mok, Ji Oh | - |
dc.contributor.author | Lee, Jae Hyuk | - |
dc.contributor.author | Lim, Soo | - |
dc.contributor.author | Kim, Sang Soo | - |
dc.contributor.author | Kim, Tae Ho | - |
dc.contributor.author | Won, Kyu Chang | - |
dc.contributor.author | Lee, Ki Young | - |
dc.contributor.author | Cho, Jae Hyoung | - |
dc.contributor.author | Han, Ju Young | - |
dc.contributor.author | Kim, So Hun | - |
dc.contributor.author | Nah, Jae Jin | - |
dc.contributor.author | Song, Hwa Rang | - |
dc.contributor.author | Lee, Si Eun | - |
dc.contributor.author | Kim, Sungrae | - |
dc.date.accessioned | 2023-05-25T07:40:17Z | - |
dc.date.available | 2023-05-25T07:40:17Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 1262-3636 | - |
dc.identifier.issn | 1878-1780 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22470 | - |
dc.description.abstract | Aims: This study evaluated the efficacy and safety of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor, versus dapagliflozin in Korean patients with type 2 diabetes mellitus (T2DM) inadequately con-trolled with metformin and gemigliptin. Methods: In this multicenter, double-blind, randomized study, patients with inadequate response to metfor-min (>= 1000 mg/day) plus gemigliptin (50 mg/day) were randomized to receive enavogliflozin 0.3 mg/day (n = 134) or dapagliflozin 10 mg/day (n = 136) in addition to the metformin plus gemigliptin therapy. The pri-mary endpoint was change in HbA1c from baseline to week 24.Results: Both treatments significantly reduced HbA1c at week 24 (-0.92% in enavogliflozin group, -0.86% in dapagliflozin group). The enavogliflozin and dapagliflozin groups did not differ in terms of changes in HbA1c (between-group difference: -0.06%, 95% confidence interval [CI]: -0.19, 0.06) and fasting plasma glucose (between-group difference: -3.49 mg/dl [-8.08;1.10]). An increase in urine glucose-creatinine ratio was sig-nificantly greater in the enavogliflozin group than in the dapagliflozin group (60.2 g/g versus 43.5 g/g, P < 0.0001). The incidence of treatment-emergent adverse events was similar between the groups (21.64% ver-sus 23.53%).Conclusions: Enavogliflozin, added to metformin plus gemigliptin, was well tolerated and as effective as dapa-gliflozin in the treatment of patients with T2DM.(c) 2023 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Masson | - |
dc.title | Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study | - |
dc.type | Article | - |
dc.publisher.location | 프랑스 | - |
dc.identifier.doi | 10.1016/j.diabet.2023.101440 | - |
dc.identifier.scopusid | 2-s2.0-85151466959 | - |
dc.identifier.wosid | 000965056700001 | - |
dc.identifier.bibliographicCitation | Diabetes and Metabolism, v.49, no.4 | - |
dc.citation.title | Diabetes and Metabolism | - |
dc.citation.volume | 49 | - |
dc.citation.number | 4 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | ADD-ON THERAPY | - |
dc.subject.keywordPlus | SGLT2 INHIBITORS | - |
dc.subject.keywordPlus | TRIPLE THERAPY | - |
dc.subject.keywordPlus | SAXAGLIPTIN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Enavogliflozin | - |
dc.subject.keywordAuthor | HbA1c | - |
dc.subject.keywordAuthor | Phase III study | - |
dc.subject.keywordAuthor | Randomized controlled study | - |
dc.subject.keywordAuthor | Sodium-glucose cotransporter 2 inhibitor | - |
dc.subject.keywordAuthor | Type 2 diabetes mellitus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.